Skip to main content
Premium Trial:

Request an Annual Quote

Angle to Raise £20M Through Stock Placement

NEW YORK — Angle on Thursday said that it plans to raise up to £20 million ($27.8 million) in a stock offering that will provide funding to continue evaluating its flagship Parsortix tumor cell-sorting system in prostate cancer, among other things.

UK-based Angle said it is offering up to 17,241,380 common shares at £1.16 apiece, which would represent roughly 7.4 percent of the company's total share capital following the placement.

Angle said that it intends to use £7 million of the proceeds to run studies of Parsortix in prostate cancer. Another £8 million from the offering will be used to support Angle's ongoing work with Parsortix in breast and ovarian cancer, which includes an ovarian cancer clinical verification study expected to report initial results in the fourth quarter, as well as accelerate the firm's pharma service business with particular emphasis on the measurement of PD-L1, a protein target for immunotherapy.

In April, Angle announced that it had struck its first large-scale pharma services contract under which an unnamed pharmaceutical partner will use Parsortix to perform longitudinal monitoring of patients in three separate global clinical trials in prostate cancer and other locally advanced and metastatic solid tumors.

A total of £3 million will be used to establish a senior management team in the US, with the remaining £2 million going to building up Angle's assay development capability. Earlier this year, Angle said it completed fitting out and staffing a clinical service lab in Plymouth Meeting, Pennsylvania.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.